Drugs / RBD1119
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07042594 | Aug 2025 → Jun 2026 overdue | — | Suzhou Ribo Life Science Co. Ltd. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-28 | Ribocure Pharmaceuticals AB | Regulatory Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease ribocure.com ↗
Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together “Ribo”) announce the submission of Phase 2 Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for RBD1119, a siRNA-based therapeutic for the treatment of coronary artery disease (CAD). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-28 | Ribocure Pharmaceuticals AB | Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic Disease ribocure.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBD1119 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07042594 ↗ |
| Route | Subcutaneous | “Subcutaneously Administered RBD1119” NCT07042594 ↗ |